miR-122 Targets Pyruvate Kinase M2 and Affects Metabolism of Hepatocellular Carcinoma

• Angela M. Liu ,

  Contributed equally to this work with: Angela M. Liu, Zhi Xu

  Affiliations Department of Pharmacology, National University of Singapore, Singapore, Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Hong Kong

  ⨯
• Zhi Xu ,

  Contributed equally to this work with: Angela M. Liu, Zhi Xu

  * E-mail: michelle.xuzhi@gmail.com (ZX); dr.johnluk@gmail.com (JML)

  Affiliation Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China

  ⨯
• Felix H. Shek,

  Affiliation Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Hong Kong

  ⨯
• Kwong-Fai Wong,

  Affiliation Cancer Science Institute, National University of Singapore, Singapore

  ⨯
• Nikki P. Lee,

  Affiliation Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Hong Kong

  ⨯
• Ronnie T. Poon,

  Affiliation Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Hong Kong

  ⨯
• Jinfei Chen,

  Affiliation Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China

  ⨯
• John M. Luk

  * E-mail: michelle.xuzhi@gmail.com (ZX); dr.johnluk@gmail.com (JML)

  Affiliations Department of Pharmacology, National University of Singapore, Singapore, Department of Surgery, National University Health System, Singapore, Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China, Cancer Science Institute, National University of Singapore, Singapore, Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Hong Kong

  ⨯